Brainsway is a fast-growing medical device company (35% YoY growth) with a wide moat and 45.6% analyst upside, but negative cash conversion and a weak chart keep it a hold.
Thesis pillars
- Wide Moat Quality→Stable
- Strong Revenue Growth→Stable
- Negative Cash Conversion→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026
Brainsway Ltd. (BWAY) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $11.09, but acceptable to hold if already in. Reasons: Earnings in 6 days (event risk); Negative momentum.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and... Read more
Hold if already holding. Not a fresh buy at $11.09, but acceptable to hold if already in. Reasons: Earnings in 6 days (event risk); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.7/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Recent developments
updated Oct 20, 2026Recent Developments — Brainsway Ltd.
Latest news
- NEWS H.C. Wainwright reiterates Brainsway stock rating on IPMG deal By Investing.com - Investing.com UK — Investing.com UK Oct 20, 2026 positive
- NEWS A Look at BrainsWay Ltd (BWAY) After 4.0% Gain -- GF Value $7.30 vs Price $11.92 - GuruFocus — GuruFocus Oct 13, 2026 positive
- NEWS BWAY Q2 2026 Earnings: EPS of $0.207 Beats Estimate by 36.5%, Shares Rise 5.3% - Short-Term Outlook - https://www.dars.g — https://www.dars.gov.et/ Oct 13, 2026 positive
- NEWS BWAY Q2 2026 Earnings: EPS of $0.207 Beats Estimate by 36.5%, Shares Rise 5.3% - Earnings Preview - https://www.dars.gov — https://www.dars.gov.et/ Oct 13, 2026 positive
- NEWS Are Options Traders Betting on a Big Move in Brainsway Stock? - TradingView — TradingView Sep 9, 2026 neutral
Latest item Oct 20, 2026 · Generated 2026-11-03T11:28:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $11.09, but acceptable to hold if already in. Reasons: Earnings in 6 days (event risk); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $16.38 (+47.7%), stop $10.67 (−3.9%), A.R:R 5.1:1. Score 6.7/10, moderate confidence.
Analyst target: $16.38 (+47.7% upside). Analyst target $16.38 (+47.7%), stop $10.67 (−3.9%), A.R:R 5.1:1. Stop-loss: $10.67.
Earnings in 6 days (event risk); Negative momentum.
Brainsway Ltd. trades at a P/E of 48.2 (forward 21.9). TrendMatrix value score: 6.0/10. Verdict: Hold.
7 analysts rate BWAY, with a consensus score of 4.3/5. 3 analysts publish price targets averaging $19.
What does Brainsway Ltd. do?BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United...
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.